Safe Harbor 10-Q: Going Concern, $7.8M Litigation Exposure and 132.2M Post-Split Shares
SHFS is trading near its 52-week low of $0.023 (2.2% above the low) on elevated volume (11× avg).
Summary
Safe Harbor's Q3 10-Q carries a going concern warning, $4.4M of cash against up to $7.8M of litigation exposure, and a share count already blown out to 132.2M by Series B conversions with ~62.9M more to come. Nasdaq delisting risk and a missed registration deadline add to the pressure.
Key Events · Earnings and Guidance · SHFS
-
Going Concern Warning Reaffirmed
Cash stood at $4.4M on September 30, 2026, down from $6.78M at year-end 2025, after a $3.8M operating loss and $4.0M of operating cash burn over the nine months. Management concluded its plans do not alleviate substantial doubt about continuing as a going concern for at least twelve months.
-
Series B Reset Drives Massive Dilution
The reverse split reset the Series B conversion price from $18.6336 to $0.1210 on October 22, 2026. Holders converted 19,529 preferred shares into 131,219,818 common shares, lifting shares outstanding from 1,028,702 to 132,248,520 by November 6, 2026; 7,605 preferred shares remain, convertible into about 62,851,246 more.
-
Abaca Litigation Overhang
A trial on damages was held August 10-11, 2026, and no ruling has issued. The company estimates a reasonably possible loss of $0 to $7.8M, and an adverse ruling near the top of that range would exceed its $4.4M of cash.
-
Nasdaq Delisting Risk Accelerating
A second 180-day compliance period runs through April 19, 2027, but the stock closed at or below $0.10 on every trading day since October 28, 2026, which allows Nasdaq to issue a Staff Delisting Determination before that date.
Analysis · SHFS · Finance
The full Q3 filing confirms the company is running out of room. Cash fell to $4.4M from $6.78M at year-end 2025, and management explicitly concludes its plans do not alleviate substantial doubt about continuing as a going concern for at least twelve months. The Abaca trial was held in August with no ruling yet; a loss anywhere near the top of the $0 to $7.8M range would exceed the cash on hand. Meanwhile the Series B conversion price reset to $0.1210 has already turned 19,529 preferred shares into 131.2M common shares, taking the count from 1.03M to 132.2M, with 7,605 preferred shares still convertible into roughly 62.9M more. The company also missed its November 6 registration deadline — a Triggering Event hits November 11 if the filing isn't made — and the stock has closed at or below $0.10 every day since October 28, which lets Nasdaq delist it before the April 19, 2027 deadline. The pending Opifex term sheet, under which Opifex holders would own about 85% of the combined company, is the only visible path out, and it blocks ELOC draws while it is in effect.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SHFS was trading at $0.02 on NASDAQ in the Finance sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.02 to $31.29. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.